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A B S T R A C T   
The mechanical properties of powders determine the ease of manufacture and ultimately the quality of the oral 
solid dosage forms. Although poor mechanical properties of an active pharmaceutical ingredient (API) can be 
mitigated by using suitable excipients in a formulation, the effectiveness of that approach is limited for high dose 
drugs or multidrug tablets. In this context, improving the mechanical properties of the APIs through solid form 
optimisation is a good strategy to address such a challenge. This work explores the powder and tableting 
properties of various lamotrigine (LAM) solid forms with the aim to facilitate direct compression by overcoming 
the poor tabletability of LAM. The two drug-drug crystals of LAM with nicotinamide and valproic acid 
demonstrate superior flowability and tabletability over LAM. The improved powder properties are rationalised 
by structure analysis using energy framework, scanning electron microscopy, and Heckel analysis.   
1. Introduction 
Since the first pharmaceutical tablet was produced in England in 
1844, the physics relating to the transformation of powdered pharma-
ceuticals into compacts has become of increasing importance to re-
searchers in pharmaceutical science (Kebler, 1914). The latest desire to 
develop directly compressible powder formulations (Bolhuis and Arm-
strong, 2006; Schaller et al., 2019) draws interesting parallels to the 
times when direct compression (DC) was the only option. The renewed 
interest in DC is partially driven by its prominent role in the continuous 
manufacturing (CM) process, which is been intensely explored by the 
pharmaceutical industry as it moves away from traditional batch pro-
cesses for better quality, efficiency, and agility of manufacturing affor-
ded by the CM (Lee et al., 2015; Mascia et al., 2013; Poechlauer et al., 
2012). CM is particularly important for green chemistry to achieve the 
significantly improved efficiency of the processes by reducing the 
number of processing steps (Li and Trost, 2008). 
Naturally, active pharmaceutical ingredients (APIs) do not always 
exhibit desired pharmaceutical properties, such as tabletability, 
compressibility, and flowability. Therefore, they need to be appropri-
ately formulated to enable successful tablet manufacturing. For a given 
powder or a powder blend, powder flow properties are often defined by 
particle size, shape and surface chemistry (Hou and Sun, 2008). Whereas 
compressibility can be described by a number of mathematical models, 
with the Heckel analysis being the most utilised to describe plastic 
deformation (Heckel, 1961; Paul and Sun, 2017a). Tabletability is the 
ability of a material to form a compact with a certain tensile strength 
across a range of compaction pressures (Joiris et al., 1998; Sun and 
Grant, 2001b). These properties are often achieved by blending an API 
with suitable excipients to overcome any deficient powder properties. 
However, for a number of challenging drugs, such as canagliflozin 
(Schaller et al., 2019) and ibuprofen (Han et al., 2013), the utility of 
excipients and design methodologies are pushed to their limits in the 
quest for a single dosage system. 
For high-API load tablets, including many multidrug systems 
(Kavanagh et al., 2018), and high dose drugs (e.g., metformin or para-
cetamol, up to 1 g per dose), the use of excipients to overcome diffi-
culties arising from deficient powder properties of APIs is limited 
because the overall size of the tablet cannot be too large to swallow 
(Dave et al., 2015). In these cases, generating solid forms with enhanced 
powder properties to reduce the quantity of excipients in formulations 
required for successful tablet manufacturing is of value (Kavanagh et al., 
2019a). 
Much of the published literature on mechanical properties of 
different solid forms compares a pair of solid forms (e.g., cocrystals, 
solvates, and salts) in a single paper (Ainurofiq et al., 2018; Hiendrawan 
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et al., 2016; Joshi et al., 2018; Karki et al., 2009; Suihko et al., 2001; 
Wang et al., 2017). This has led to useful information but gaining 
comprehensive understanding of the crystal structure–mechanical 
property relationships would benefit from simultaneous investigation of 
several crystal forms in a single study, which is beginning to emerge in 
the literature (Sanphui et al., 2015; Yadav et al., 2020). We synthesised 
several solid forms of lamotrigine (LAM, Scheme 1) with a variety of 
structures to probe the effect of crystal packing on the mechanical 
characteristics (Fig. 1). These include lamotrigine-acetic acid (LAMAA), 
lamotrigine-isopropanol (LAMIPA), and lamotrigine-chloride (LAMCL) 
in addition to two drug-drug complexes, lamotrigine-nicotinamide hy-
drate (LAMNIC) and lamotrigine-valproic acid (LAMVAL) (Kavanagh 
et al., 2019b). 
2. Materials and methods 
Lamotrigine was purchased from Baoji Guokang Bio-Technology Co. 
Ltd. and used without further purification. All other solvents and re-
agents were purchased from Sigma-Aldrich and used as received. 
2.1. Synthesis of solid forms 
All solid forms were synthesised by following published methods. 
Phase purity of each powder was confirmed by PXRD. The powders were 
sieved and only the 100–180 µm size fractions were further charac-
terised because such a size range is typical of drugs for direct compaction 
(Shekunov et al., 2007). 
Lamotrigine chloride salt. 8 g Lamotrigine was added to a solution 
containing 100 mL 10 M HCl and stirred at 500 rpm for 48 h. The 
product was recovered by vacuum filtration, washed with ice cold water 
and then dried in air. 
Lamotrigine/valproic acid (1:2) ionic cocrystal. 8 g lamotrigine was 
added to a 100 mL solution containing excess valproic acid (10 mL) and 
stirred at 500 rpm for 48 h. The product was recovered by vacuum 
filtration, washed with ice cold water and then dried in air. 
Lamotrigine/acetic acid (1:2) ionic cocrystal. 8 g lamotrigine was 
added to 100 mL acetic acid and stirred at 500 rpm for 48 h. The product 
was recovered by vacuum filtration, washed with ice cold water and 
then dried in air. 
Lamotrigine/isopropyl alcohol (IPA) solvate. 8 g lamotrigine was added 
to 100 mL IPA and stirred at 500 rpm for 48 h. The product was 
recovered by vacuum filtration and then dried in air. 
Lamotrigine/nicotinamide (1:1) cocrystal hydrate. Lamotrigine (to 0.5 
M) was added to a 100 mL water containing 3.5 M nicotinamide in 2% 
w/w sodium lauryl sulphate and stirred at 500 rpm for 48 h. The product 
was recovered by vacuum filtration, washed with ice cold water and 
then dried in air. 
2.2. Powder characterisation 
Powder true density was determined for each solid form using a 
helium pycnometer (AccuPyc II 1340 Micrometrics Instrument Corp, 
UK), sample density was determined after 10 cycles. Powder rheology 
was determined using an FT4 powder rheometer (Freeman Technology, 
Tewkesbury, UK). Compressibility is defined as the percentage volume 
change under a specified compression pressure up to 15 kPa. Powder 
permeability determines the ease of air to pass through the powder bed 
whilst it is compressed under a 15 kPa pressure, which is described by a 
modified Darcy’s law (Cordts and Steckel, 2012). Powders are pre-
conditioned with a helical blade prior to testing to ensure repeatability. 
Raman spectra of the powders and tablet immediately after 
compaction were collected using a Raman spectrometer (LabRAM HR 
Evolution, Horiba, UK) with a 514 nm excitation laser, 350–1650 cm− 1 
scan range, and 4 cm− 1 resolution using a 50 × objective lens with 60 s 
exposure time, 50% laser power, and 4 accumulated scans per spectrum. 
X-ray powder diffraction (XRPD) patterns were collected in 
Bragg–Brentano geometry on a PANalytical Empyrean diffractometer 
equipped with a sealed tube (Cu Kα12, λ = 1.5418 Å) an 1D X’Celerator 
detector between 4 and 40◦ 2θ. Variable temperature PXRD data were 
collected in Bragg–Brentano geometry on a X’Pert MPD Pro equipped 
with an Anton-Paar TK450 stage, a sealed tube (Cu Kα12, λ = 1.5418 Å) 
and a 1D X’Celerator detector in the 4–30◦ (2θ) range. 
Microphotographs of each sample were collected after placing it onto 
a carbon tape and then sputter coated with gold–palladium for 90 s with 
a 20 mA current. Samples were then scanned at 2.5 kV with 16 mm 
working distance using a high-resolution field-emission electron mi-
croscope (SEM, Hitachi SU-70, Hitachi, Japan). 
Scheme 1. Molecular structure of lamotrigine.  
LAM (EFEMUX01) LAMIPA (IJAHOR) LAMNIC (WUVKII)
LAMVAL (ROSYIK) LAMCL (YUCRAQ) LAMAA (LIBXUR)
Fig. 1. Structures of six LAM solid forms (CSD refcodes are in parentheses).  
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2.3. Tablet preparation 
A single punch press (Gamlen Instruments, UK) equipped with a 
GTP-500-010 load cell was used to generate flat, cylindrical tablets of 6 
mm diameter with an average thickness of 3 mm. Approximately 105 mg 
of sample was weighed on an analytical balance and transferred to die 
manually to generate a ~100 mg tablet (due to loss of powder on 
transfer). Compacts were made with one-sided compression and no pre- 
compression at pressures of 35, 70, 105, 140, and 175 MPa without 
holding at the peak pressure. Punch speed was 1 mm/s. Compaction data 
was collected at a sampling rate of 200 data points per second. Tablets 
were then stored in sealed polyethylene bags for 24 h to enable stress 
relaxation. All compacts were made with the same compaction param-
eters. Ejection data was collected at maximum pressure (175 MPa) at the 
same punch speed and sampling rate. Each tablet was prepared in 
triplicate. 
2.4. Tablet characterisation 
Tablet dimensions were measured using a digital calliper and dia-
metrical breaking strength of the tablet was conducted on a hardness 
tester (PTB 311E, Pharma Test, Germany) 
Tablet porosity was calculated according to Eq. (1): 




Tensile strength was calculated using Eq. (2): 
Tensile strength =
2 × (Breaking strength)
π × (Diameter) × (Thickness) (2) 




× 100 (3)  
where hpressure is the powder bed height at maximum pressure and h is the 
thickness of the tablet after compaction at constant diameter (6 mm). 
2.5. Heckel analysis 
The in-die tablet porosity - pressure data was analysed using Eq. (4) 
(Heckel, 1961; Sun and Grant, 2001a): 
− ln(1 − tablet porosity) = KP+A (4)  
where P is the compaction pressure, K is the slope of the linear portion of 
the Heckel plot and A is the y-axis intercept. The mean yield pressure, Py 
= 1/K, was calculated to assess plasticity of the powders. 
2.6. Computational structure analysis 
The crystal morphology and attachment energy were calculated 
using the Morphology module in the Materials Studio 8.0. (Biovia 
Software Inc., San Diego, CA, USA). Calculations were carried out using 
the following parameters: Compass force field with associated charges at 
fine quality (Li et al., 2017), the “Ewald” electrostatic summation 
method, “atom based” van der Waals summation, and a minimum dhkl of 
0.8 Å. 
The pairwise intermolecular interaction energy was estimated using 
CrystalExplorer (Turner et al., 2017) and Gaussian09 (Frisch et al., 
2009) with experimental crystal geometry. Considering the uncertainty 
of hydrogen position by single crystal X-ray diffraction, the hydrogen 
positions were normalised to standard neutron diffraction values during 
the calculation. The total intermolecular interaction energy for a given 
pair of molecules, is calculated using the CE-B3LYP electron densities 
model consisting of the electrostatic, polarisation, dispersion, and 
exchange-repulsion components, with scale factors of 1.057, 0.740, 
0.871, and 0.618, respectively, (Turner et al., 2014). The intermolecular 
interactions between molecules with separation distance more than 3.8 
Å are ignored. The intermolecular interaction energies are represented 
by cylinders connecting the centres of mass of molecules with the cyl-
inder thickness proportional to the interaction energy (Turner et al., 
2015). 
The quantitative layer topology analysis in crystals was obtained 
using CSD Python program (Bryant et al., 2018). This geometric analysis 
approach identified the most likely slip plane based on the lowest degree 
of interpenetration and highest distance between the separated molec-
ular layers. 
3. Results and discussion 
All powders were phase pure based on their PXRD patterns (Fig. 2). 
Table 1 summarises their Py and true densities. 
Different mechanical properties of powders are expected to affect the 
choice of the most suitable solid form for use in a tablet formulation. Key 
characteristics of drugs, such as tabletability, compressibility and 
flowability, must be determined to understand how a powder will 
perform during the manufacturing processes to assure the quality of 
tablets. These properties are often affected by the shape and size of the 
particles (Sun and Grant, 2001b). For pure drug powders, the shape and 
size of crystals or crystal agglomerates can largely explain their different 
flowability (Fu et al., 2012; Ridgway and Rupp, 1969). 
As the same narrow sieve fractions of all of the powders were used, 
we focused on the particle morphology to explain their different flow-
abilities. Based on the SEM micrographs (Fig. 3), the powders of the 6 
solid forms can be classified into three morphological groups, 1) smooth, 
round crystals (LAMNIC, LAMIPA and LAMAA), 2) large agglomerates of 


















Fig. 2. Powder XRD diffractograms of six lamotrigine solid forms in compari-
son to patterns calculated from crystal structures deposited in the Cambridge 
Structural Database. 
Table 1 
Summary of solid form characteristics.  
Solid 
form 
CSD code True density (g/ 
cm3) 
(n = 10) 
(mean ± SE) 
Py (MPa) 





(n = 3) 
(mean ± SE) 
LAM EFEMUX01 1.5612 ± 0.0007 66.5 ± 7.0 5.65 ± 0.14 
LAMVAL ROSYIK 1.2431 ± 0.0010 54.3 ± 3.8 10.28 ± 0.09 
LAMAA LIBXUR 1.4434 ± 0.0013 81.9 ± 15 6.28 ± 0.19 
LAMIPA IJAHOR 1.5193 ± 0.0009 117.2 ±
1.6 
5.20 ± 0.25 
LAMNIC WUVKII 1.5016 ± 0.0010 142.6 ±
37.3 
5.89 ± 0.23 
LAMCL YUCRAQ 1.6399 ± 0.0022 68.3 ± 3.2 8.95 ± 0.34  
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consisting of fine needles (LAMVAL). Agglomeration leads to powder 
properties distinct from the primary crystals, which can effect flow-
ability, densification processes during tableting, and the tabletability 
(Bika et al., 2001). 
Before a pharmaceutical solid is compacted it must flow through 
various hoppers and pipes to reach the tablet press. Therefore, it is useful 
to determine powder rheology of the various LAM solid forms (Fig. 4). 
Poor powder permeability can lead to capping or lamination of 
tablets alongside difficulties with dosage uniformity (Prescott and Bar-
num, 2000). The powder permeability follows the descending order of 
LAMNIC > LAMIPA > LAM = LAMCL = LAMAA > LAMVAL (Fig. 4a). 
This rank order can be rationalised from the SEM images, which iden-
tified three predominant macroscopic shapes (Fig. 3): 1) the large 
smooth LAMNIC and LAMIPA crystals tend to create less tortuous voids 
within the powder bed to enable easy air permeation, 2) the rougher 
shaped agglomerates of LAM and LAMCL and 3) the needle shaped 
morphology of LAMVAL lead to interlocked particles packing, which 
reduces the air permeability of these powders. 
Compressibility is another parameter that correlates with flow 
properties. Among the 6 powders, compressibility follows the descend-
ing order of LAMCL > LAMNIC > LAM = LAMAA = LAMVAL > LAMIPA 
(Fig. 4b). According to the European Pharmacopeia monograph on 
powder flow, the measured compressibility suggests that the flow of 
LAMCL is “very, very poor”, those of LAM, LAMAA, LAMVAL and 
LAMNIC are “very poor”, and that of LAMIPA is “poor” (although it is 
very close to “passable”). As such, all of the powders could be described 
as unsuitable for further development and addition of excipients would 
be required to improve their powder properties (Council of Europe, 
2019). Although beyond the scope of this study, the use of magnesium 
stearate (York, 1975) or colloidal silica (Tran et al., 2019; Zhou et al., 
2013) could be used to improve their flow characteristics. However, the 
use of magnesium stearate for flow enhancement needs to be balanced to 
avoid any excessive detrimental effects on tablet strength (Strickland 
et al., 1956). 
For particles of comparable sizes, those with smoother surfaces and 
more spherical shapes are generally expected to exhibit better flow 
properties than needle-like materials (Beck et al., 2010; Ridgway and 
Rupp, 1969). However, the compressibility of LAMVAL lies in the 
middle of the group, while that of LAMCL is the highest. This observa-
tion is inconsistent with the large and relatively round agglomerates of 
LAMVAL than LAMCL. A possible explanation is that these agglomerates 
are loosely packed, and they break into fine crystals under stress during 
the compressibility test. These observations highlight the fact that ac-
curate prediction of powder properties from particle properties remains 
a challenge in the powder technology field. In general, reliable powder 
properties still need to be experimentally determined, due to the wide 
variety of confounding factors (Chen et al., 2020; Krantz et al., 2009). 
The goal of powder compression is to obtain a tablet that is strong 
enough to withstand stresses during manufacturing, distribution, and 




Fig. 3. Scanning Electron Microscopy (SEM) images of solid forms of LAM (250x magnification, scale 200 μm).  
Fig. 4. Flowability of six LAM powders (a) permeability and (b) compressibility.  
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In general, 0.15 porosity is commonly the aim for compacted pharma-
ceuticals with an acceptable tensile strength of 1.5 MPa, as previously 
discussed (Podczeck, 2013, 2012; Sonnergaard, 2013). As such, the 
tabletability, compressibility, and compactibility of the solid forms were 
analysed. 
Only LAMVAL, LAMIPA and LAMAA could form intact tablets over 
the entire range of compaction pressures tested (Fig. 5a). LAMNIC and 
LAM could not form intact tablet below 70 MPa and 140 MPa, respec-
tively. Except for LAMCL, all lamotrigine solids can form tablets with a 
tensile strength greater than 1 MPa (Fig. 5a). When normalised by tablet 
porosity, tensile strength appears to fall in a common zone (Fig. 5b). 
Among the five crystals with intact tablets available, LAMVAL is the 
most compressible, yielding tablets with the lowest porosity at any given 
pressure (Fig. 5c). Based on limited tablet porosity data, the compress-
ibility of LAM appears to be the worst (highest porosities), while the 
compressibilities of LAMIPA, LAMNIC, and LAMAA lie in between and 
cannot be well separated from each other due to the large variations in 
data (Fig. 5c). Within the precision of measured data, the comparable 
compactibility among the five crystals suggests comparable bonding 
strength. Since the bonding strengths do not significantly differ, the 
different tabletabilities is a result of different bonding area according to 
the bonding area – bonding strength interplay model for tablet tensile 
strength (Osei-Yeboah et al., 2016). This is supported by the corre-
spondence between the highest tabletability and best compressibility for 
LAMVAL as well as the lowest tabletability and poorest compressibility 
for LAM (Fig. 5a,c). Following this trend, the inability of LAMCL to form 
intact tablets at any of the pressures tested may be attributed to its 
exceedingly poor compressibility. This is possible if LAMCL exhibits very 
low plasticity, which leads to small bonding area in the tablet. 
A powder with a lower mean yield pressure (Py) is more plastic 
(Heckel, 1961; Sun and Grant, 2001c). By this measure, the plasticity of 
the materials follows the descending order of LAMVAL > LAM ≈ LAMCL 
> LAMAA > LAMIPA > LAMNIC (Fig. 6 and Table 1). This rank order 
differs from that based on compressibility (Fig. 5c). The discrepancy 
may be attributed to the complex particle deformation mechanisms 
during compression, including rearrangement, fragmentation, elastic, 
and plastic deformation (Leuenberger and Rohera, 1986). All of these 
mechanisms can have an influence on bonding area formed between 
particles in a tablet, but in-die Heckel analysis can only capture the 
Fig. 5. Compression properties of the six LAM solid forms. a) Tabletability b) Compactibility, and c) Compressibility.  
Fig. 6. In-die Heckel analysis of the six solid forms of LAM.  
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contributions due to plastic deformation. Thus, although the Heckel 
analysis remains a useful tool in studying tablet compression (Rue and 
Rees, 1978; Sun and Grant, 2001c), other relevant properties, such as 
bonding strength and particle size, must be considered along with 
Heckel analysis to more accurately predict tableting behaviour of 
powders. 
Changes in crystal packing can lead to considerable changes in 
crystal mechanical properties (Karki et al., 2009; Mishra and Sun, 2020). 
For example, the different compaction properties between orthorhombic 
and monoclinic polymorphs of paracetamol could be explained by their 
different topological features of stacking molecular layers (Di Martino 
et al., 1996). This is one of the reasons why solid form screening is a 
cornerstone of research and development for new drugs (Aaltonen et al., 
2009). Since the seminal work by Pertsin and Kitaigorodsky (Pertsin and 
Kitaigorodsky, 1987), a significant amount of work on predicting me-
chanical properties from crystal structures has been published (Chen 
et al., 2020; Roberts et al., 2000; Singaraju et al., 2020; Sun and Grant, 
2001a). Although initial efforts relied on visual analysis of crystal 
structures, more quantitative crystal structure analysis techniques, such 
as energy framework and crystal structure topology analysis, have 
improved the ability to predict crystal mechanical properties from 
crystal structure (Turner et al., 2015; Wang and Sun, 2019, 2018). 
Within this context, energy framework (Fig. 7) and crystal structure 
topology analysis (Table 2) were employed to understand the powder 
behaviour of the various solids of LAM. 
The LAM crystal has multiple intersecting planes, i.e., (200), 
(11 − 1), (110), and (20 − 2), with similar attachment energies 
(− 102.31, − 138.39, − 139.4 and − 145.54 kcal/mol, respectively). The 
topology analysis also revealed the 3D hydrogen bonding network 
(Table. 2). Therefore, LAM is expected to exhibit a low plasticity during 
compaction because of the absence of a facile slip plane from energetic 
perspective. However, the (10–1) could serve as slip plane based on the 
positive layer distance. LAMIPA has intersecting planes (100), (002) 
and (011), covering similar facet areas (39, 18 and 37%) and with 
similar interaction energies (− 193, − 127 and − 131 kcal/mol). Hence, 
this crystal is also not expected to exhibit appreciable plasticity. 
LAMNIC also has a number of intersecting planes, (10–1), (001), (010), 
with attachment energies of − 56, − 33 and − 39 kcal/mol and covering 
facet areas of the crystal of 16, 37 and 29%, respectively. LAMAA reveals 
























Fig. 7. Energy frameworks for lamotrigine solid forms.  
Table 2 
Key results from the topology analysis and morphology prediction of the six 












LAM 3D lattice (10 − 1) 0.86 6.29 2.08 
LAMAA 2D sheet (10 − 2) − 0.44 5.50 2.17 
LAMCL 2D sheet (100) 1.22 16.26 6.50 
LAMVAL 2D sheet (10 − 1) − 2.0 21.35 3.24 
LAMIPA 2D sheet (10 − 3) − 1.38 6.31 2.03 
LAMNIC 3D lattice (001) 0.24 14.18 2.49  
* Negative value means layer interdigitated. 
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(− 151, − 120 and − 90 kcal/mol), suggesting difficulty with plastic 
deformation during compression. 
LAMVAL crystal shows a more anisotropic distribution of interaction 
energies, revealing a possible slip plane of (10 − 1) with relatively low 
attachment energy of − 90 kcal/mol. This makes it possible for the 
LAMVAL crystal to undergo plastic deformation through slip of the 
(10 − 1) planes. Although all the layers are interdigitated (Table 2), the 
large (70%) facet area of the (10 − 1) further magnifies the anisotropy of 
LAMVAL (the second highest aspect ratio among the predicted crystal 
morphology). Thus, compared to the previous four LAM crystal forms, 
the activation of slip plane (10 − 1) leads to higher plasticity of the 
LAMVAL powder during compression. The energy framework confirmed 
that there are stacking (10 − 1) molecular layers, with weak interlayer 
interaction energy, which can shear along the b direction. 
The energy framework of LAMCL (Fig. 7) also reveals anisotropic 
interaction energies and a possible slip plane of (100), which has 
significantly lower attachment energy (− 18 kJ/mol) and the largest 
interlayer distance (1.22 Å). The (100) facet also accounts for approx-
imately 70% of the facet area in the calculated crystal morphology. 
Therefore, LAMCL is expected to exhibit better plasticity than LAMVAL. 
However, this is not the case as its Py is higher than both LAM and 
LAMVAL (Table 1). Moreover, it exhibits the worst tabletability in this 
series and no intact tablets could be formed, despite better plasticity 
predicted from energy framework and Py than other three LAM crystal 
forms. To either confirm or exclude the possibility of solid form changes 
induced by compaction (Chan and Doelker, 1985; Matsumoto et al., 
1991; Otsuka, 1993), Raman spectroscopy was performed on powders 
and compressed tablets. However, no any sign of phase changes induced 
by compression were observed (Fig. 8). 
We then investigated the elastic recovery (Table 1) and ejection 
forces (Fig. 9) to better understand the different tabletabilities of various 
LAM solid forms, as high values in these variables have been linked to 
the introduction of defects into tablets upon ejection (Paul and Sun, 
2017b; Singaraju et al., 2020). The elastic recovery of the solid forms 
follows the descending order of LAMVAL > LAMCL > LAMAA >
LAMNIC ≈ LAM > LAMIPA. Although LAMVAL has the highest elastic 
recovery, it has the best tableting properties. With the exception of 
LAMCL, the other forms have similar elastic recovery. In-die ejection 
forces (Fig. 9) descend in the order of LAM > LAMCL > LAMAA ≈
LAMIPA ≈ LAMNIC > LAMVAL. The high ejection forces of LAM and 
LAMCL may contribute to their poor tabletability (Fig. 5a). This is 
consistent with the observation that the relatively low ejection force of 
LAMVAL tablets corresponds to good tabletability (Fig. 5a). However, 
further investigation is required to explain the discrepancy between 
predicted and observed tabletability of LAMCL. 
4. Conclusion 
This work illustrates that it is possible to modulate the mechanical 
properties of LAM by modifying crystal structures through the formation 
of multi-component solids. Although LAMIPA and LAMNIC have the 
best powder flow properties, all the powders fail the flowability criteria 
for direct compression. Hence, all crystal forms will need to be formu-
lated to ensure they have adequate flow for successful tablet 
manufacturing. The different flow properties could be rationalised by 
different crystal morphologies, but flow properties of agglomerates may 
still be poor due to fragmentation under stress. Among the six crystal 
forms, LAMVAL has the best tableting properties, which may be attrib-
uted to the presence of slip planes in its crystal structure. The observa-
tion that both LAMVAL and LAMNIC exhibit improved tableting 
properties than the parent drug (LAM) suggests that, when possible, the 
formation of multidrug crystals may be a more effective approach over 
simply blends of different drug crystals for direct compression. In such 























































































































































































































































a)89 ± 5 MPa 169 ± 17.9 MPa
46 ± 0.7 MPa133 ± 7.2 MPa176 ± 2.8 MPa
LAMCLLAM
95 ± 4.4 MPa/mm2
83 ± 5.9 MPa/mm2
60 ± 4.4 MPa/mm2
67 ± 7 MPa/mm2 64 ± 1.9 MPa/mm2 10 ± 0.3 MPa/mm2
LAMAA LAMIPA LAMVAL
LAMNIC
Fig. 9. Tablet ejection profiles annotated with maximum ejection pressure and area under curve of the six solid forms of LAM after compaction at 175 MPa (n = 3).  
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cases, less excipients are needed to attain adequate tabletability so that 
smaller tablets can be prepared to deliver the same amount of drug. 
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Tran, D.T., Majerová, D., Veselý, M., Kulaviak, L., Ruzicka, M.C., Zámostný, P., 2019. On 
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